Clinical Trial Update: Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-PD-1 antibody in combination with peg-asparaginase and chidamide for early-stage NK/T-cell lymphoma; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasal Nk T-cell Lymphoma
• Nk T-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Chidamide (chidamide)
• PEG-asparaginase (polyethylene glycol-asparaginase)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Immune Checkpoint Inhibitor, Chemotherapy Effect | Phase 2 | Status: UNKNOWN